HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henkel Q3

This article was originally published in The Rose Sheet

Executive Summary

In personal care, "hair, cosmetics and skin care businesses performed particularly well" in the third quarter, contributing to 3% sales growth and an 11.7% jump in operating profit to $52.3 mil., German company reports during Nov. 17 sales and earnings call. Consolidated operating profit grew 7.4% to $204.3 mil., and net earnings rose 11.3% to $140 mil. in the period. Sales grew 3.8% after currency adjustment, but were flat at $2.8 bil. on a constant basis. Third quarter charge of $101 mil. related to restructuring is nearly offset by gain of $96.3 mil. from sale of stake in Wella. Personal care sales are anticipated to grow in the high single digits for the full year following currency adjustments, while overall sales are expected to increase more than 4% after adjusting for currency and acquisitions/divestitures...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel